Skip to main content
Erschienen in: International Journal of Hematology 5/2015

01.11.2015 | Case Report

Identification of the SOX5 gene as a novel IGH-involved translocation partner in BCL2-negative follicular lymphoma with t(12;14)(p12.2;q32)

verfasst von: Masayuki Shiseki, Akihiro Masuda, Kentaro Yoshinaga, Naoki Mori, Michiko Okada, Toshiko Motoji, Junji Tanaka

Erschienen in: International Journal of Hematology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Chromosome translocations involving the immunoglobulin heavy chain (IGH) gene locus at chromosome region 14q32 are often observed in B-cell lymphoid neoplasms. Of these, t(14;18)(q32;q21) results in juxtaposition of the IGH gene on chromosome 14 and the BCL2 gene on chromosome 18, leading to the overexpression of BCL2 anti-apoptotic protein, which plays a critical role in the development of follicular lymphoma (FL). However, BCL2 overexpression is not observed in approximately 10 % of FL, and the molecular pathogenesis of BCL2-negative FL has not been elucidated. Here, we identify the SRY-related high-morbidity-group (HMG) box 5 (SOX5) gene on chromosome 12p12 as a novel IGH-involved translocation partner in the case of BCL2-negative follicular lymphoma (FL) with a complex karyotype including t(12;14)(p12.2;q32) by long-distance inverse PCR. As a result of this translocation, the SOX5 gene is juxtaposed to the enhancer of the IGH gene; SOX5 overexpression in neoplastic cells was demonstrated by immunohistochemistry. The results of the present study suggest a role for SOX5 in the molecular pathogenesis of FL.
Literatur
1.
Zurück zum Zitat Skinnder BF, Horsman DE, Dupuis B, Gascoyne RD. Bcl-6 and bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Human Pathol. 1999;30:803–8.CrossRef Skinnder BF, Horsman DE, Dupuis B, Gascoyne RD. Bcl-6 and bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Human Pathol. 1999;30:803–8.CrossRef
2.
Zurück zum Zitat Zha H, Raffeld M, Charboneau L, Pittaluga S, Kwak LW, Petricoin E 3rd, et al. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest. 2004;84:235–44.CrossRefPubMed Zha H, Raffeld M, Charboneau L, Pittaluga S, Kwak LW, Petricoin E 3rd, et al. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest. 2004;84:235–44.CrossRefPubMed
3.
Zurück zum Zitat Karube K, Guo Y, Suzumiya J, Sugita Y, Nomura Y, Yamamoto K, et al. CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood. 2007;109:3076–9.PubMed Karube K, Guo Y, Suzumiya J, Sugita Y, Nomura Y, Yamamoto K, et al. CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood. 2007;109:3076–9.PubMed
4.
Zurück zum Zitat Leich E, Salaverria I, Bea S, Zettl A, Wright G, Moreno V, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood. 2009;114:826–34.PubMedCentralCrossRefPubMed Leich E, Salaverria I, Bea S, Zettl A, Wright G, Moreno V, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood. 2009;114:826–34.PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Leich E, Zamo A, Horn H, Haralambieva E, Puppe B, Gascoyne RD, et al. MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. Blood. 2011;118:5550–8.PubMedCentralCrossRefPubMed Leich E, Zamo A, Horn H, Haralambieva E, Puppe B, Gascoyne RD, et al. MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. Blood. 2011;118:5550–8.PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat Shiseki M, Kitagawa Y, Wang YH, Yoshinaga K, Kondo T, Kuroiwa H, et al. Lack of nucleophosmin gene mutations in myeloid malignaincies with chromosome 5 abnoralities. Leuk Lymphoma. 2007;48:2141–4.CrossRefPubMed Shiseki M, Kitagawa Y, Wang YH, Yoshinaga K, Kondo T, Kuroiwa H, et al. Lack of nucleophosmin gene mutations in myeloid malignaincies with chromosome 5 abnoralities. Leuk Lymphoma. 2007;48:2141–4.CrossRefPubMed
7.
Zurück zum Zitat Willis TG, Jadayel DM, Coignet LJA, Abdul-Rauf M, Treleaven JG, Catovsky D, et al. Rapid molecular cloning of rearrangement of the IGHJ locus using long-distance inverse polymerase chain reaction. Blood. 1997;90:2456–64.PubMed Willis TG, Jadayel DM, Coignet LJA, Abdul-Rauf M, Treleaven JG, Catovsky D, et al. Rapid molecular cloning of rearrangement of the IGHJ locus using long-distance inverse polymerase chain reaction. Blood. 1997;90:2456–64.PubMed
8.
Zurück zum Zitat Okada M, Suto Y, Hirai M, Shiseki M, Usami A, Okajima K, et al. Microarray CGH analyses of chromosomal 20q deletions in patients with hematopoietic malignancies. Cancer Genet. 2012;205:18–24.CrossRefPubMed Okada M, Suto Y, Hirai M, Shiseki M, Usami A, Okajima K, et al. Microarray CGH analyses of chromosomal 20q deletions in patients with hematopoietic malignancies. Cancer Genet. 2012;205:18–24.CrossRefPubMed
9.
Zurück zum Zitat Wunderle VM, Critcher R, Ashworth A. Good fellow PN. Cloning and characterization of SOX5, a new member of the human SOX gene family. Genomics. 1996;36:354–8.CrossRefPubMed Wunderle VM, Critcher R, Ashworth A. Good fellow PN. Cloning and characterization of SOX5, a new member of the human SOX gene family. Genomics. 1996;36:354–8.CrossRefPubMed
10.
Zurück zum Zitat Lefebvre V, Dumitriu B, Penzo Mendez A, Han Y, Pallavi B. Control of cell fate and differentiation by sry-related high-morbidity-group box (Sox) transcriptional factors. Int J Biochem Cell Biol. 2007;39:2195–214.PubMedCentralCrossRefPubMed Lefebvre V, Dumitriu B, Penzo Mendez A, Han Y, Pallavi B. Control of cell fate and differentiation by sry-related high-morbidity-group box (Sox) transcriptional factors. Int J Biochem Cell Biol. 2007;39:2195–214.PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Ueda R, Yoshida K, Kawase T, Kawakami Y, Toda M. Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients. Int J Cancer. 2007;120:1704–11.CrossRefPubMed Ueda R, Yoshida K, Kawase T, Kawakami Y, Toda M. Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients. Int J Cancer. 2007;120:1704–11.CrossRefPubMed
12.
Zurück zum Zitat Huang DY, Lin YT, Jan PS, Hwang YC, Liang ST, Peng Y, et al. Transcriptional factor SOX-5 enhances nasopharyngeal carcinoma progression by down-regulating SPARC gene expression. J Pathol. 2008;214:445–55.CrossRefPubMed Huang DY, Lin YT, Jan PS, Hwang YC, Liang ST, Peng Y, et al. Transcriptional factor SOX-5 enhances nasopharyngeal carcinoma progression by down-regulating SPARC gene expression. J Pathol. 2008;214:445–55.CrossRefPubMed
13.
Zurück zum Zitat Ma S, Chan YP, Woolcock B, Hu L, Wong KY, Ling MT, et al. DNA fingerprinting tags novel altered chromosomal regions and identifies the involvement of SOX5 in the progression of prostate cancer. Int J Cancer. 2009;124:2323–32.CrossRefPubMed Ma S, Chan YP, Woolcock B, Hu L, Wong KY, Ling MT, et al. DNA fingerprinting tags novel altered chromosomal regions and identifies the involvement of SOX5 in the progression of prostate cancer. Int J Cancer. 2009;124:2323–32.CrossRefPubMed
14.
Zurück zum Zitat Harris ML, Baxter LL, Loftus SK, Pavan WJ. Sox proteins in melanocyte development and melanoma. Pigment Cell Melanoma Res. 2011;23:496–513.CrossRef Harris ML, Baxter LL, Loftus SK, Pavan WJ. Sox proteins in melanocyte development and melanoma. Pigment Cell Melanoma Res. 2011;23:496–513.CrossRef
15.
Zurück zum Zitat Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics. 2008;1:13–29.PubMedCentralCrossRefPubMed Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics. 2008;1:13–29.PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Ehrhardt GRA, Hijikata A, Kitamura H, Ohara O, Wang J-Y, Cooper MD. Discriminating gene expression profiles of memory B cell subpopulation. J Exp Med. 2008;205:1807–17.PubMedCentralCrossRefPubMed Ehrhardt GRA, Hijikata A, Kitamura H, Ohara O, Wang J-Y, Cooper MD. Discriminating gene expression profiles of memory B cell subpopulation. J Exp Med. 2008;205:1807–17.PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Charles ED, Brunetti C, Marukian S, Ritola KD, Talal AH, Marks K, et al. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood. 2011;117:5425–37.PubMedCentralCrossRefPubMed Charles ED, Brunetti C, Marukian S, Ritola KD, Talal AH, Marks K, et al. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood. 2011;117:5425–37.PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Moore CR, Edwards SKE, Xie P. Targeting TRAF3 downstream signaling pathways in B-cell neoplasms. J Cancer Sci Ther. 2015;7:67–74.PubMedCentralPubMed Moore CR, Edwards SKE, Xie P. Targeting TRAF3 downstream signaling pathways in B-cell neoplasms. J Cancer Sci Ther. 2015;7:67–74.PubMedCentralPubMed
19.
Zurück zum Zitat Storlazzi CT, Albano F, Lo Cunsolo C, Doglioni C, Guastadisegni MC, Impera L, et al. Upregulation of the SOX5 by promoter swapping with the P2RY8 gene in primary splenic lymphoma. Leukemia. 2007;21:2221–5.CrossRefPubMed Storlazzi CT, Albano F, Lo Cunsolo C, Doglioni C, Guastadisegni MC, Impera L, et al. Upregulation of the SOX5 by promoter swapping with the P2RY8 gene in primary splenic lymphoma. Leukemia. 2007;21:2221–5.CrossRefPubMed
20.
Zurück zum Zitat Zafarana G, Gilles AJM, van Gurp RJHLM, Olsson PG, Elstrodt F, Stoop H, et al. Coamplification of DAD-R, SOX5, and EKI1 in human testicular seminomas, with specific overexpression of DAD-R, correlates with reduced levels of apoptosis and earlier clinical manifestation. Cancer Res. 2002;62:1822–31.PubMed Zafarana G, Gilles AJM, van Gurp RJHLM, Olsson PG, Elstrodt F, Stoop H, et al. Coamplification of DAD-R, SOX5, and EKI1 in human testicular seminomas, with specific overexpression of DAD-R, correlates with reduced levels of apoptosis and earlier clinical manifestation. Cancer Res. 2002;62:1822–31.PubMed
21.
Zurück zum Zitat Cheung KJJ, Delaney A, Ben-Neriah S, Schein J, Lee T, Shah SP, et al. High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes. Genes Chromosomes Cancer. 2010;49:669–81.CrossRefPubMed Cheung KJJ, Delaney A, Ben-Neriah S, Schein J, Lee T, Shah SP, et al. High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes. Genes Chromosomes Cancer. 2010;49:669–81.CrossRefPubMed
Metadaten
Titel
Identification of the SOX5 gene as a novel IGH-involved translocation partner in BCL2-negative follicular lymphoma with t(12;14)(p12.2;q32)
verfasst von
Masayuki Shiseki
Akihiro Masuda
Kentaro Yoshinaga
Naoki Mori
Michiko Okada
Toshiko Motoji
Junji Tanaka
Publikationsdatum
01.11.2015
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 5/2015
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-015-1823-z

Weitere Artikel der Ausgabe 5/2015

International Journal of Hematology 5/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.